52 research outputs found

    Optimization of the gas flow in a GEM chamber and development of the GEM foil stretcher

    Get PDF
    The gas electron multiplier technology has been proven to tolerate rat e larger than 50 MHz/cm2 without noticeable aging and to provide sub resolution on working chambers up to 45 cm x 45 cm. A new gas electron multiplier-based tracker is under development for the Hall A upgrade at Jefferson Lab. The chambers of the tracker have been designed in a modular way: each chamber consists of 3 adjacent gas electron multiplier modules, with an active area of 40 cm x 50 cm each. We optimized the gas flow inside the gas electron multiplier module volume, using the COMSOL physics simulator framework; the COMSOL-based analysis includes the design of the inlet and outlet pipes and the maximization of the uniformity of the gas flow. We have defined the procedures for the assembling of the gas electron multiplier modules and designed a mechanical system (TENDIGEM) that will be used to stretch the GEM foils at the proper tension (few kg/cm); the TENDIGEM is based on the original design developed at LNF

    Optimization of the gas flow in a GEM chamber and development of the GEM foil stretcher

    Full text link
    The gas electron multiplier technology has been proven to tolerate rat e larger than 50 MHz/cm2 without noticeable aging and to provide sub resolution on working chambers up to 45 cm x 45 cm. A new gas electron multiplier-based tracker is under development for the Hall A upgrade at Jefferson Lab. The chambers of the tracker have been designed in a modular way: each chamber consists of 3 adjacent gas electron multiplier modules, with an active area of 40 cm x 50 cm each. We optimized the gas flow inside the gas electron multiplier module volume, using the COMSOL physics simulator framework; the COMSOL-based analysis includes the design of the inlet and outlet pipes and the maximization of the uniformity of the gas flow. We have defined the procedures for the assembling of the gas electron multiplier modules and designed a mechanical system (TENDIGEM) that will be used to stretch the GEM foils at the proper tension (few kg/cm); the TENDIGEM is based on the original design developed at LNF

    OPTIMIZATION OF THE GAS FLOW IN A GEM CHAMBER AND DEVELOPMENT OF THE GEM FOIL STRETCHER

    Full text link
    The Gas Electron Multiplier (GEM) technology has been proven to tolerate rate larger than 50 MHz/cm 2 without noticeable aging and to provide sub millimeter resolution on working chambers up to 45x45 cm

    Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study

    Full text link
    Background Cancer survivors-people living with and beyond cancer-are a growing population with different health needs depending on prognosis and time since diagnosis. Despite being increasingly necessary, complete information on cancer prevalence is not systematically available in all European countries. We aimed to fill this gap by analysing population-based cancer registry data from the EUROCARE-6 study. Methods In this population-based study, using incidence and follow-up data up to Jan 1, 2013, from 61 cancer registries, complete and limited-duration prevalence by cancer type, sex, and age were estimated for 29 European countries and the 27 countries in the EU (EU27; represented by 22 member states that contributed registry data) using the completeness index method. We focused on 32 malignant cancers defined according to the third edition of the International Classification of Diseases for Oncology, and only the first primary tumour was considered when estimating the prevalence. Prevalence measures are expressed in terms of absolute number of prevalent cases, crude prevalence proportion (reported as percentage or cases per 100 000 resident people), and age-standardised prevalence proportion based on the European Standard Population 2013. We made projections of cancer prevalence proportions up to Jan 1, 2020, using linear regression. Findings In 2020, 23 711 thousand (95% CI 23 565-23 857) people (5 center dot 0% of the population) were estimated to be alive after a cancer diagnosis in Europe, and 22 347 thousand (95% CI 22 210-22 483) in EU27. Cancer survivors were more frequently female (12 818 thousand [95% CI 12 720-12 917]) than male (10 892 thousand [10 785-11 000]). The five leading tumours in female survivors were breast cancer, colorectal cancer, corpus uterine cancer, skin melanoma, and thyroid cancer (crude prevalence proportion from 2270 [95%CI 2248-2292] per 100 000 to 301 [297-305] per 100 000). Prostate cancer, colorectal cancer, urinary bladder cancer, skin melanoma, and kidney cancer were the most common tumours in male survivors (from 1714 [95% CI 1686-1741] per 100 000 to 255 [249-260] per 100 000). The differences in prevalence between countries were large (from 2 to 10 times depending on cancer type), in line with the demographic structure, incidence, and survival patterns. Between 2010 and 2020, the number of prevalent cases increased by 3 center dot 5% per year (41% overall), partly due to an ageing population. In 2020, 14 850 thousand (95% CI 14 681-15 018) people were estimated to be alive more than 5 years after diagnosis and 9099 thousand (8909-9288) people were estimated to be alive more than 10 years after diagnosis, representing an increasing proportion of the cancer survivor population. Interpretation Our findings are useful at the country level in Europe to support evidence-based policies to improve the quality of life, care, and rehabilitation of patients with cancer throughout the disease pathway. Future work includes estimating time to cure by stage at diagnosis in prevalent cases. Copyright (c) 2024 Elsevier Ltd. All rights reserved

    Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study

    Full text link
    Background: Management of lymphoid malignancies requires substantial health system resources. Total national health expenditure might influence population-based lymphoid malignancy survival. We studied the long-term survival of patients with 12 lymphoid malignancy types and examined whether different levels of national health expenditure might explain differences in lymphoid malignancy prognosis between European countries and regions. Methods: For this observational, retrospective, population-based study, we analysed the EUROCARE-6 dataset of patients aged 15 or older diagnosed between 2001 and 2013 with one of 12 lymphoid malignancies defined according to International Classification of Disease for Oncology (third edition) and WHO classification, and followed up to 2014 (Jan 1, 2001-Dec 31, 2014). Countries were classified according to their mean total national health expenditure quartile in 2001-13. For each lymphoid malignancy, 5-year and 10-year age-standardised relative survival (ASRS) was calculated using the period approach. Generalised linear models indicated the effects of age at diagnosis, gender, and total national health expenditure on the relative excess risk of death (RER). Findings: 82 cancer registries (61 regional and 21 national) from 27 European countries provided data eligible for 10-year survival estimates comprising 890 730 lymphoid malignancy cases diagnosed in 2001-13. Median follow-up time was 13 years (IQR 13-14). Of the 12 lymphoid malignancies, the 10-year ASRS in Europe was highest for hairy cell leukaemia (82·6% [95% CI 78·9-86·5) and Hodgkin lymphoma (79·3% [78·6-79·9]) and lowest for plasma cell neoplasms (29·5% [28·9-30·0]). RER increased with age at diagnosis, particularly from 55-64 years to 75 years or older, for all lymphoid malignancies. Women had higher ASRS than men for all lymphoid malignancies, except for precursor B, T, or natural killer cell, or not-otherwise specified lymphoblastic lymphoma or leukaemia. 10-year ASRS for each lymphoid malignancy was higher (and the RER lower) in countries in the highest national health expenditure quartile than in countries in the lowest quartile, with a decreasing pattern through quartiles for many lymphoid malignancies. 10-year ASRS for non-Hodgkin lymphoma, the most representative class for lymphoid malignancies based on the number of incident cases, was 59·3% (95% CI 58·7-60·0) in the first quartile, 57·6% (55·2-58·7) in the second quartile, 55·4% (54·3-56·5) in the third quartile, and 44·7% (43·6-45·8) in the fourth quartile; with reference to the European mean, the RER was 0·80 (95% CI 0·79-0·82) in the first, 0·91 (0·90-0·93) in the second, 0·94 (0·92-0·96) in the third, and 1·45 (1·42-1·48) in the fourth quartiles. Interpretation: Total national health expenditure is associated with geographical inequalities in lymphoid malignancy prognosis. Policy decisions on allocating economic resources and implementing evidence-based models of care are needed to reduce these differences. Funding: Italian Ministry of Health, European Commission, Estonian Research Council

    Latest Results on the Radiation Tolerance of Diamond Detectors

    Get PDF

    Future Opportunities in Accelerator-based Neutrino Physics

    Full text link
    International audienceThis document summarizes the conclusions of the Neutrino Town Meeting held at CERN in October 2018 to review the neutrino field at large with the aim of defining a strategy for accelerator-based neutrino physics in Europe. The importance of the field across its many complementary components is stressed. Recommendations are presented regarding the accelerator based neutrino physics, pertinent to the European Strategy for Particle Physics. We address in particular i) the role of CERN and its neutrino platform, ii) the importance of ancillary neutrino cross-section experiments, and iii) the capability of fixed target experiments as well as present and future high energy colliders to search for the possible manifestations of neutrino mass generation mechanisms

    Track Reconstruction with Cosmic Ray Data at the Tracker Integration Facility

    Full text link
    The subsystems of the CMS silicon strip tracker were integrated and commissioned at the Tracker Integration Facility (TIF) in the period from November 2006 to July 2007. As part of the commissioning, large samples of cosmic ray data were recorded under various running conditions in the absence of a magnetic field. Cosmic rays detected by scintillation counters were used to trigger the readout of up to 15\,\% of the final silicon strip detector, and over 4.7~million events were recorded. This document describes the cosmic track reconstruction and presents results on the performance of track and hit reconstruction as from dedicated analyses
    corecore